Apimeds Pharmaceuticals US Inc
APUS | AMEX
$3.00
$0.00 (-0.17%)
Nov 2, 2026, 11:55 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | -58.17M | -40.66M | -6M | -5.16M | -3.71M | -1.5M | -1.39M | -1.65M | -1.42M | -1.01M | -777.69K | -285.32K | -175.3K | -139.23K | -74.59K |
Depreciation & Amortization | 45.8K | 25.75K | 5.71K | 1.72K | 232 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 42.67K | 42.67K | 42.67K | 42.67K | n/a | n/a | n/a | n/a | -1 | 22.44K | 69.99K | 118.38K | 118.38K | 95.94K | 48.39K |
Other Working Capital | 1.76M | -1.3M | -2.82M | -2.07M | -1.97M | 876.33K | 538.75K | 575.69K | 291.99K | 48.31K | 41.84K | -173.23K | -2.66K | -2.16K | -2.16K |
Other Non-Cash Items | 42.46M | 30.84M | -151.73K | 1.97M | 2.01M | 128.84K | 117.72K | 95.15K | 70.6K | 56.73K | 38.07K | 33K | 24.91K | 16.66K | 8.41K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 1.76M | -1.3M | -2.82M | -2.07M | -1.97M | 876.33K | 538.75K | 575.69K | 291.99K | 48.31K | 41.84K | -173.23K | -2.66K | -2.16K | -2.16K |
Operating Cash Flow | -13.86M | -11.05M | -8.93M | -5.21M | -3.67M | -490.74K | -733.53K | -974.48K | -1.06M | -882.06K | -627.79K | -307.17K | -34.67K | -28.78K | -19.96K |
Capital Expenditures | -53.37K | -66.73K | -57.34K | -35.91K | -13.36K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -2M | -2M | -2M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 2M | 500K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -8M | -8M | -8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -8.06M | -9.57M | -10.06M | -35.91K | -13.37K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | 14.02M | 10.05M | 9.3M | 250K | 400K | 400K | 150K | 150K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -237.1K | -331.7K | -314.5K | 100 | 100 | 193.7K | 176.5K | -455K | 568.1K | 468.1K | 477.1K | 1.32M | 291.9K | 291.9K | 282.9K |
Financial Cash Flow | 13.46M | 21.35M | 20.62M | 12.2M | 12.35M | 593.7K | 326.5K | 250K | 1.12M | 1.02M | 1.03M | 1.32M | 291.9K | 291.9K | 282.9K |
Net Cash Flow | -456.95K | 8.73M | 9.63M | 6.96M | 8.67M | 102.96K | -407.03K | -724.48K | 62.87K | 141.04K | 404.31K | 1.01M | 257.23K | 263.12K | 262.95K |
Free Cash Flow | -13.92M | -11.11M | -8.98M | -5.24M | -3.68M | -490.74K | -733.53K | -974.48K | -1.06M | -882.06K | -627.79K | -307.17K | -34.67K | -28.78K | -19.96K |
Adj. Free Cash Flow | -13.96M | -11.16M | -9.03M | -5.29M | -3.68M | -490.74K | -733.53K | -974.48K | -1.06M | -904.5K | -697.78K | -425.55K | -153.05K | -124.72K | -68.34K |
Maintenance CapEx | -14.87K | -15.1K | -5.71K | -1.72K | -232 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | -38.5K | -51.63K | -51.63K | -34.19K | -13.13K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -13.88M | -11.06M | -8.93M | -5.21M | -3.67M | -490.74K | -733.53K | -974.48K | -1.06M | -882.06K | -627.79K | -307.17K | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove APUS